Heat Shock Protein Response Pathway In Neurodegeneration represents a key pathological mechanism in neurodegenerative diseases. This page explores the molecular and cellular processes involved, their contribution to disease progression, and therapeutic implications.
Heat shock proteins (HSPs) are molecular chaperones that play critical roles in protein folding, aggregation prevention, and cellular proteostasis. The heat shock protein response is a conserved cellular defense mechanism that becomes dysregulated in neurodegenerative diseases. Enhancing HSP activity represents a promising therapeutic strategy for conditions characterized by protein misfolding and aggregation, including Alzheimer's disease, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis.
flowchart TD
A[Cellular Stress] --> B[Protein Misfolding] -->
A --> C[Oxidative Stress] -->
A --> D[Heat Shock] -->
B --> E[Aggregated Proteins] -->
C --> E
D --> E
E --> F[HSF1 Activation] -->
F --> G[HSF1 Trimerization] -->
G --> H[HSP Transcription] -->
H --> I[HSP70 Family] -->
H --> J[HSP90 Family] -->
H --> K[HSP40 Family] -->
H --> L[Small HSPs] -->
I --> M[Protein Folding] -->
I --> N[Aggregation Prevention] -->
I --> O[Proteasome Delivery] -->
J --> P[Client Maturation] -->
J --> Q[Aggregate Solubilization] -->
K --> R[Substrate Targeting] -->
L --> S[Cytoprotection] -->
M --> T[Proteostasis Restoration] -->
N --> T
O --> T
P --> T
Q --> T
R --> T
S --> T
T --> U[Cell Survival]
| Component |
Function |
Disease Relevance |
| HSF1 |
Heat shock transcription factor 1 |
Master regulator |
| HSF2 |
Heat shock transcription factor 2 |
Development |
| HSP70 |
Major chaperone (HSPA1A, HSPA8) |
Aggregate clearance |
| HSP90 |
Client protein maturation |
Kinase quality control |
| HSP40 |
Co-chaperone, substrate delivery |
DnaJ homologs |
| HSP27 |
Small HSP, anti-apoptotic |
(HSPB1) |
| αB-crystallin |
Small HSP (CRYAB) |
Lens, muscle, CNS |
| Bag1 |
HSP70 co-chaperone |
Anti-apoptotic |
| CHIP |
E3 ligase, quality control |
(STUB1) |
The HSP70 family constitutes the major inducible chaperone system:
- Protein folding: HSP70 assists de novo protein folding using ATP hydrolysis
- Aggregation prevention: Binds hydrophobic regions to prevent aberrant interactions
- Refolding: Can rescue proteins from early aggregation states
- Proteasome targeting: Delivers ubiquitinated proteins for degradation
- Autophagy: Directs aggregates to autophagosomes via LAMP2A
HSP90 is essential for maturation and stability of signaling proteins:
- Kinase quality control: HSP90 buffers polymorphic kinases
- Steroid receptors: Maturation of nuclear hormone receptors
- Aggregate clearance: Can solubilize preformed aggregates
- Therapeutic target: HSP90 inhibitors in cancer and neurodegeneration
Small heat shock proteins form large oligomers with unique functions:
- αB-crystallin (CRYAB): Major sHSP in brain; binds misfolded proteins
- HSP27 (HSPB1): Anti-apoptotic; stabilizes actin cytoskeleton
- HSP20 (HSPB6): Cardioprotective; implicated in vascular dementia
HSPs interact with Aβ and tau pathology:
- HSP70: Binds Aβ oligomers; reduces toxicity
- HSP90: Regulates tau phosphorylation kinases
- αB-crystallin: Colocalizes with neurofibrillary tangles
- Therapeutic: HSP70 inducers (geranylgeranylacetone) tested
HSPs protect against α-synuclein toxicity:
- HSP70: Most effective against α-synuclein aggregation
- HSP90: Regulates LRRK2 kinase activity
- HSP40: DnaJB family members with α-synuclein specificity
- Therapeutic: AAV-HSP70, HSP90 inhibitors in trials
HSPs modulate mutant huntingtin aggregation:
- HSP70: Prevents aggregation; improves motor function in models
- HSP40: DnaJ family enhances HSP70 activity
- HSP90: Client proteins include mutant huntingtin
- Therapeutic: HSP inducers show promise in HD models
HSPs protect against SOD1 and TDP-43 pathology:
- HSP70: Binds mutant SOD1; reduces aggregation
- HSP90: Regulates TDP-43 client proteins
- αB-crystallin: Implicated in ALS astrocyte pathology
- Therapeutic: HSP co-inducers in preclinical models
- Geranylgeranylacetone (GGA): FDA-approved gastric ulcer drug
- Arimoclomol: HSP co-inducer in ALS trials
- 17-DMAG: HSP90 inhibitor with HSP70 induction
- Recombinant HSP70: Purified protein delivery
- Cell-penetrant versions: Engineered delivery peptides
- Exosome delivery: Natural carrier systems
- AAV-HSP70: Viral vector delivery to CNS
- AAV-HSP40: DnaJB family members
- Combination: Multiple HSPs for enhanced effect
- HSP90 inhibitors: Geldanamycin derivatives (17-AAG, 17-DMAG)
- HSP70 activators: Allosteric activators in development
- Co-chaperone modulators: Bag1, HOP, CHIP targeting
- HSF1 activation: Phosphorylation status
- HSP70 levels: Peripheral blood mononuclear cells
- HSP90 activity: Client protein stabilization
- Aggregate-bound HSPs: Autopsy tissue studies
| Agent |
Target |
Disease |
Phase |
Status |
| Arimoclomol |
HSP co-inducer |
ALS |
Phase 3 |
Completed |
| Geranylgeranylacetone |
HSP70 inducer |
AD |
Phase 2 |
Completed |
| 17-DMAG |
HSP90 inhibitor |
ALS |
Phase 1 |
Completed |
| HSP70 protein |
Direct delivery |
PD |
Phase 1 |
Planning |
The study of Heat Shock Protein Response Pathway In Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Shorter J. (2011). The mammalian disaggregase and sHSPs in protein aggregation. Cold Spring Harb Perspect Biol. PMID: 21865409
- Kim HJ, et al. (2013). Therapeutic modulation of HSP70 in neurodegeneration. Trends Pharmacol Sci. PMID: 23566768
- Pratt WB, et al. (2015). HSP90 and HSP70 in protein quality control. Mol Endocrinol. PMID: 25751636
- Balchin D, et al. (2016). HSP90 in protein folding and proteostasis. Cell. PMID: 27020753
- Auluck PK, et al. (2002). HSP70 chaperones suppress α-synuclein toxicity. Science. PMID: 11976275
- Cummings CJ, et al. (2001). Overexpression of HSP70 reduces polyglutamine aggregation. Nat Med. PMID: 11217881
- Kalia SK, et al. (2010). Hsp70 and parkinsonism. Exp Neurol. PMID: 20691137
- Bence KK, et al. (2005). HSP70 in protein aggregation diseases. Nat Rev Neurosci. PMID: 15803161
- Yerbury JJ, et al. (2013). The extracellular chaperone clusterin. Cell Stress Chaperones. PMID: 23572437
- Jinwal UK, et al. (2009). HSP90 inhibition in Alzheimer disease. J Pharmacol Exp Ther. PMID: 19139270
🔴 Low Confidence
| Dimension |
Score |
| Supporting Studies |
10 references |
| Replication |
0% |
| Effect Sizes |
25% |
| Contradicting Evidence |
0% |
| Mechanistic Completeness |
75% |
Overall Confidence: 39%